Author/Editor | Vrtovec, Bojan; Okrajšek, Renata; Goličnik, Alenka; Ferjan, Mateja; Starc, Vito; Radovancevic, Branislav | |
Title | Atorvastatin therapy increases heart rate variability, decreases QT variability, and shortens QTc interval duration in patients with advanced chronic heart failure | |
Type | članek | |
Source | J Card Fail | |
Vol. and No. | Letnik 11, št. 9 | |
Publication year | 2005 | |
Volume | str. 684-90 | |
Language | eng | |
Abstract | Background: Although statins decrease the incidence of ventricular arrhythmias in patients with atherosclerotic heart disease, their potential antiarrhythmic effects in heart failure remain undefined. Methods and Results: Of 80 heart failure patients enrolled, 40 were randomized to receive atorvastatin (statin group); the remaining 40 served as controls. At baseline and after 3 months, we measured heart rate variability (HRV), QT variability (QTV), and QTc interval using interactive high-resolution electrocardiogram analysis. The 2 groups did not differ in baseline HRV standard deviation of nornuil-to-normal intervals (SDNN) (RR): 24.6 ± 2.8 ms in statin group versus 24.8 ± 3.1 ms in controls, P = .72; square root of the mean of squared differcncas between successive intervals (rMSSD) (RR): 21.2 + 2.7 ms versus 21.7 ± 2.9 ms, P = .43), QTV SDNN (QT): 6.4 ± 1.5 ms versus 6.4±1.7, P = .96; rMSSD QT): 9.0 ± 2.4 ms versus 8.7 ± 2.9 ms, P = .65, and QTc interval 450 ± 30 ms versus 446 ± 27 ms, P = .59. At 3 months, the statin group displayed higher HRV SDNN RR): 27.2 ± 4.9 ms versus 24.4 ± 2.8 ms in controls, P = .003; rMSSD RR: 24.7 ` 4.2 ms versus 21.3 ± 5.6 ms, P = .004, lower QTV SDNN (QT): 5.1 ± 1.9 ms versus 6.5+- 2.1, P = .004; rMSSD (QT): 6.6+- 2.8 ms versus 8.8 ± 3.1 ms, P = .002, and shorter QTc interval 437 ± 29 ms versus 450 ± 25 ms, P = .03 than the control group. Conclusions: Atorvastatin increases HRV, decreases QTV, and shortens QTc interval, and may thereby reduce the risk of arrhythmias in patients with advanced heart failure. | |
Descriptors | HEART FAILURE, CONGESTIVE ARRHYTHMIA HEART RATE HYDROXYMETHYLGLUTARYL COA REDUCTASES ANTI-ARRHYTHMIA AGENTS SEX FACTORS ELECTROCARDIOGRAPHY HEPTANOIC ACIDS PYRROLES SURVIVAL ANALYSIS TREATMENT OUTCOME PROSPECTIVE STUDIES |